Erenumab Displays Success in Patients Who Failed 2 or More Preventative Migraine Treatments
The calcitonin gene-related peptide inhibitor lowered monthly migraine days by ≥50% in 30.3% of patients compared to 13.7% on placebo.
Neurology Comic: Low-Res Memory
A photographic memory with low resolution images.
Practice Guideline Update: 5 Important Facts About MCI
Here: the most notable changes in the new AAN guideline on mild cognitive impairment.
PTC Therapeutics, CHDI Foundation Announce Partnership for Small-Molecule Compounds in Huntington
The program seeks to optimize small-molecule compounds to decrease the production of mHtt through PTC’s splicing platform.
Are You a Promising Scholar?
This is a unique opportunity for talented early career psychiatrists and neurologists to gain experience in scholarly activities and research.
PIP4Kγ Inhibition Shown to Reduce mHtt Levels, Displays Promise for Huntington
Using the NCT-504 compound to inhibit cell-signaling activity in PIP4Kγ resulted in an increase in autophagy in connective tissue cells from patients with HD.
Vagus Nerve Stimulation Shows Promise for Stroke Recovery
Vagus nerve stimulation in conjunction with conventional rehabilitation services more than doubled lasting recovery in forelimb supination and simple motor tasks following a stroke.
Eating Disorders Linked to Subthreshold Autism Spectrum Disorder
What's the link between restrictive anorexia, anorexia nervosa, and binge eating disorder and ASD? This study sheds some light.
Gut-Immune System-Brain Axis and Neuropsychiatric Disorders
Alterations in the gut microbiome may trigger autoimmunity against the CNS, and contribute to the development of neuropsychiatric disorders. How? A recent review offers insights.
FDA Approves Subcutaneous Immunoglobulin for CIDP
The treatment is the first patient-infused subcutaneous formulation of immunoglobulin to gain approval for CIDP.
Serious Accidents Increased in Epilepsy
Epilepsy appears to be the main reason for an increased risk of serious traffic accidents among patients with the disease -not anti-epileptic drugs.
PERK-ATF4 Pathway Holds Promise for Oxidative Stress Protection in Huntington Disease
Exposure to monesin has been shown to combat stress by oxidants and free radicals via the protein kinase R-like endoplasmic reticulum kinase/activating transcription factor 4 pathway.
New Biomarker for Neuropsychiatric Events in Lupus?
This study points to nitrated nucleosomes as a promising biomarker for distinguishing neuropsychiatric events due to systemic lupus erythematosus from those secondary to other disorders.
FDA Accepts Solriamfetol Application for Excessive Sleepiness
The FDA has accepted an application for solriamfetol as a treatment for excessive sleepiness associated with narcolepsy or obstructive sleep apnea, with a PDUFA action date set for December 20, 2018.
ARVs Linked to Worse Neurodevelopment in Young Children
Children exposed to antiretrovirals (ARVs) may have worse neurodevelopmental outcomes than children never exposed to ARVs according to a systematic review and meta-analysis.
Mini Quiz: Deep Brain Stimulation for Memory Impairment
Which brain regions are potential deep brain stimulation targets for neurological disorders with memory impairment? Take the quiz and learn more.
AbbVie, Voyager Therapeutics Announce Collaboration on AAV Vector Therapies for Neurodegenerative Conditions
The goal for the companies is to reach greater levels of anti-tau antibodies in a single treatment that what current weekly or bi-weekly infusions can achieve.
FDA Accepts Application for Inhaled Levodopa for OFF Periods in PD
The FDA had accepted a new drug application for the inhaled levodopa therapy for the treatment of OFF period symptoms in patients with Parkinson disease who are taking a carbidopa/levodopa regimen.
FDA Green Lights Amantadine Extended-Release Tablets for Parkinson Disease
The once-daily therapy will be available in 3 doses—129 mg, 193 mg, and 258 mg—giving patients flexibility in regimen setting among the options.
FDA Clears 24-Hour Treatment Window for Trevo Clot Retriever
The FDA has expanded the approval for the Trevo clot retrieval device to allow for thrombectomy up to 24 hours after the development of symptoms in patients with acute ischemic stroke.
How Real Are Vibes: The Good and the Bad?
The perception of good vibes and bad vibes is among the most difficult human experiences to define. The feeling that something “feels right” or that something “just isn’t right” has been attributed to multiple factors.
FDA Clears Generic Glatiramer Acetate Injection for Relapsing Multiple Sclerosis
The injection therapy now has an indication for use in either 40 mg/mL or 20 mg/mL doses, with the lower dose having been approved in June 2015.
Levetiracetam Proves Favorable to Phenobarbital for Infants with NSE
In a head-to-head comparison, levetiracetam was shown to increase the rate of infants free of monotherapy failure by 28% more than phenobarbital in pediatric patients with nonsyndromic epilepsy.
Encephalitis Lethargica: The Still Unexplained Sleeping Sickness
The encephalitis lethargica epidemic of 1916-1930 is estimated to have affected at least half a million of people in Europe and still remains a mystery.
Shared Genes for 5 Major Neuropsychiatric Disorders?
Research points to a genetic etiology for 5 major psychiatric disorders. Do these disorders have shared genes?
Embrace Smartwatch Gets FDA Go-Ahead for Seizure Monitoring
The smartwatch detected 40 generalized tonic-clonic seizures with 100% accuracy in a supporting clinical trial of 135 patients.
Neurology Comic: Insurance Headache
Is there a treatment for this?
Dronabinol Effective for Obstructive Sleep Apnea
The synthetic cannabis-like therapy dronabinol was effectively used to treated patients with obstructive sleep apnea, offering a potentially better alternative to CPAP machines.
Saliva: A New Tool for Concussion Diagnosis?
Recognizing the need for objective markers of brain injury, researchers have dedicated extensive efforts to developing concussion biomarkers.
Treatment Induced Neuropathy of Diabetes: Underrecognized But on the Rise?
Treatment-induced neuropathy of diabetes, also called insulin neuritis, may be more common than previously thought.